Skip to main content

Group B Streptococcal Infection

3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

MinervaX
MinervaXDenmark - Copenhagen
2 programs
2
GBS-NN/NN2Phase 21 trial
GBS-NN/NN2 VaccinePhase 2Vaccine1 trial
Active Trials
NCT04596878Completed205Est. May 2023
NCT05154578Completed269Est. Oct 2023
Pfizer
PfizerNEW YORK, NY
1 program
1
GBS6Phase 21 trial
Active Trials
NCT05832502Unknown300Est. Sep 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
PfizerGBS6
MinervaXGBS-NN/NN2 Vaccine
MinervaXGBS-NN/NN2

Clinical Trials (3)

Total enrollment: 774 patients across 3 trials

Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE)

Start: Oct 2022Est. completion: Sep 2025300 patients
Phase 2Unknown
NCT05154578MinervaXGBS-NN/NN2 Vaccine

Immunogenicity and Safety of GBS-NN/NN2 in Pregnant Women

Start: Feb 2022Est. completion: Oct 2023269 patients
Phase 2Completed

Study of a Group B Streptococcus Vaccine in Pregnant Women Living With HIV and in Pregnant Women Who do Not Have HIV

Start: Nov 2020Est. completion: May 2023205 patients
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.